NASDAQ GS
ARIA

ARIAD Pharmaceuticals, Inc.

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of ARIAD Pharmaceuticals, Inc. (NASDAQ GS: ARIA) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ARIAD Pharmaceuticals, Inc. (“ARIAD” or the “Company”) (NASDAQ GS: ARIA) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Takeda Pharmaceutical Company Limited (“Takeda”), in a transaction valued at approximately $5.2 billion.

Under the terms of the agreement, shareholders of ARIAD will receive $24.00 in cash for each share of ARIAD common stock.

The investigation concerns whether ARIAD’s board of directors failed to adequately shop the Company and obtain the best possible value for ARIAD shareholders before entering into an agreement with Takeda.

If you own the common stock of ARIAD and purchased your shares before January 9, 2017, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.